Last checked at 
22 Jan 2018 10:00
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 31 December 2017
Net Assets | £234m |
Net Assets per share | 624p |
Share price | 625p |
Total value of unquoted investments | £20m |
Total number of portfolio companies | 92 |
Dividend | 4% of NAV per annum |
Top Ten Quoted Investments
Company Name | % NAV |
Biogen | 6.5 |
Celgene | 6.3 |
Regeneron | 4.8 |
Nektar | 4.0 |
Exelixis | 3.9 |
Vertex | 3.6 |
Adamas | 3.4 |
Acadia | 3.2 |
Genmab | 3.0 |
Gilead | 2.8 |
----------- | |
Total | 41.5 |
Geographical Allocation | % NAV |
US & Canada | 90 |
Europe & UK | 10 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 92 |
Unquoted | 8 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 37 |
Mid Cap =USD1-10BN | 34 |
Small Cap | 29 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 39 |
Rare diseases | 14 |
CNS | 11 |
Ophthalmology | 7 |
Inflammation | 7 |
Infectious Diseases | 5 |
Metabolic | 5 |
Medtech | 3 |
Other | 9 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
22 JANUARY 2018